来那替尼
医学
不利影响
曲妥珠单抗
内科学
安慰剂
肿瘤科
乳腺癌
佐剂
辅助治疗
癌症
病理
替代医学
作者
Hiroji Iwata,Norikazu Masuda,Sung‐Bae Kim,Kentaro Inoue,Yoshiaki Rai,Takashi Fujita,Joanne Chiu,Shoichiro Ohtani,Masato Takahashi,Toshiko Miyaki,Yen‐Shen Lu,Binghe Xu,Yoon Sim Yap,Anita Zarina Bustam,Bin Yao,Bo Zhang,Richard Bryce,Arlene Chan
出处
期刊:Future Oncology
[Future Medicine]
日期:2019-07-01
卷期号:15 (21): 2489-2501
被引量:7
标识
DOI:10.2217/fon-2019-0143
摘要
Aim: To evaluate the efficacy and safety of neratinib as extended adjuvant therapy in patients from Asia based on exploratory analyses of the Phase III ExteNET trial. Patients & methods: A total of 2840 women with early stage HER2-positive breast cancer were randomly assigned to neratinib 240 mg/day or placebo for 1 year after trastuzumab-based adjuvant therapy. Results: A total of 341 patients were from Asia (neratinib, n = 165; placebo, n = 176). 2-year invasive disease-free survival rates were 92.8 and 90.8% with neratinib and placebo, respectively (HR: 0.70; 95% CI: 0.31-1.55), and 5-year rates were 91.9 and 87.2%, respectively (HR: 0.57; 95% CI: 0.27-1.13). Diarrhea was the most common adverse event with neratinib. Conclusion: Extended adjuvant therapy with neratinib reduces disease recurrences in Asian women with HER2-positive breast cancer. Trial registration: Clinicaltrials.gov NCT00878709.
科研通智能强力驱动
Strongly Powered by AbleSci AI